- Report
- March 2024
- 351 Pages
Global
From €4749EUR$4,950USD£4,107GBP
- Report
- February 2024
- 86 Pages
Global
From €4749EUR$4,950USD£4,107GBP
- Report
- November 2023
- 190 Pages
Global
From €4701EUR$4,900USD£4,065GBP
- Report
- February 2024
- 172 Pages
Global
From €4701EUR$4,900USD£4,065GBP
- Report
- January 2022
- 242 Pages
Global
From €4605EUR$4,799USD£3,982GBP
- Report
- May 2023
- 86 Pages
Global
From €3500EUR$3,908USD£3,132GBP
- Book
- April 2018
- 472 Pages
- Book
- August 2010
- 656 Pages
Therapeutic Antibody Engineering is a field of biotechnology that focuses on the development of antibodies for therapeutic use. These antibodies are designed to target specific molecules or cells in the body, and can be used to treat a variety of diseases. The process of engineering therapeutic antibodies involves the use of recombinant DNA technology to create antibodies with desired properties. This technology is used to modify existing antibodies or to create new ones from scratch.
The therapeutic antibody engineering market is driven by the increasing demand for treatments for diseases such as cancer, autoimmune diseases, and infectious diseases. The market is also driven by advances in technology, which have enabled the development of more effective and efficient therapeutic antibodies.
Some companies in the therapeutic antibody engineering market include AbbVie, Amgen, AstraZeneca, Biogen, Genentech, GlaxoSmithKline, Merck, Novartis, Pfizer, and Regeneron. Show Less Read more